Search 

Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

TheraCryf is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

TheraCryf exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

ViaNautis swas spun out of UCL from the laboratories of Prof. Giueseppe Battaglia in 2018. 

Following a successful, oversubscribed late seed funding, the company now works from labs at the Babraham Research Campus. The company’s proprietary technology, PolyNaut® can be applied to both clinical and non clinical/ex vivo products.

ViaNautis works with pharma and biotech partners for innovation and problem solving in neurology, oncology and immune diseases. Our partners Abcam PLC market and develop non-clinical products.